Status: Not yet recruiting
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation
Participants needed: 250
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: LG ChemUpdated: Aug 7, 2026
Eligibility criteria
Males and females aged 18 years or older [+5]
Investigational therapy or anti-cancer therapy within 21 days or 5 half-lives pr... [+9]